The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer

201648 citationsJournal Articlegold Open Access

Authors

Ofer N. Gofrit · Hadassah Medical Center

Vladimir Yutkin · Hadassah Medical Center

Amos Shapiro · Hadassah Medical Center

Galina Pizov · Hadassah Medical Center

Kevin C. Zorn

Guy Hidas · Hadassah Medical Center

Ilan Gielchinsky · Hadassah Medical Center

Abstract

A patient with variant bladder cancer treated with intravesical immunotherapy has a 27% chance of dying from this disease within 5 years compared to 7.5% chance for a patient with conventional high-grade UC.

Topics & Keywords

Bladder and Urothelial Cancer Treatments Urinary and Genital Oncology Studies Urinary Tract Infections Management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Frontiers in Oncology

Volume 6, pp. 43-43

DOI: 10.3389/fonc.2016.00043

Field-Weighted Citation Impact: 5.96